Head and neck cancer therapy response interpretation (Hopkins criteria)

Changed by Henry Knipe, 19 Apr 2018

Updates to Article Attributes

Title was changed:

~~Hopkins criteria. -~~ Head and neck ~~PET/CT. Therapy~~cancer therapy response interpretation (Hopkins criteria.)

Status changed from pending review to published (public).

Published At was set to .

Body was changed:

Show markup changes

The~~Hopkins head~~ head and ~~Neck~~neck cancer therapy response interpretation (Hopkins criteria), is a qualitative system of interpretation for therapy response assessment using PET CT-CT.

Background

Widely used options for therapy response assessment are clinical examination, histopathology, CT and MR imaging, however, they have variable diagnostic accuracy^1,2. ~~(1,2)~~

~~18 F FDG~~18F-FDG PET~~/CT~~-CT is useful in the ~~diagnosis~~diagnosis, staging, therapy assessment, and follow-up of ~~Head~~head and neck squamous cell ~~cancer~~carcinoma (HNSCC) (3^3,4).

Pretreatment 18F-FDG PET~~/CT~~-CT is useful in accurate staging and prediction of disease recurrence as well as survival ~~(5)~~⁵.

Post-treatment 18F-FDG PET~~/CT~~-CT is useful in evaluating treatment response, detecting recurrence ~~(6)~~⁶, predicting outcomes and survival (7^7,8).

These criteria ~~has a substantial~~have substantial interreader agreement, high negative predictive value, and can predict overall survival and progression-free survival in patients with HNSCC⁹.(9

Criteria

Five-point qualitative post-therapy assessment scoring system (Hopkins criteria)

~~Squamous cell tumors of the~~ for head and neck ~~is the most frequent.~~

~~Strongly associated risk factors~~ ~~(10)~~PET-CT:~~- tobacco use.- alcohol consumption.- human papillomavirus (HPV) infection.~~

~~Five-Point Qualitative Posttherapy Assessment Scoring System (Hopkins Criteria) for Head and Neck PET/CT~~

Response category ~~18 F~~18F-FDG uptake at the primary site and nodes less than ~~IJV~~internal jugular vein (IJV). Complete metabolic response.
Focal 18 F-FDG uptake at the primary site and nodes greater than IJV but less than liver. Likely complete metabolic response.
Diffuse 18 F-FDG uptake at the primary site or nodes is greater than IJV or liver. Likely postradiation inflammation.
Focal 18 F-FDG uptake at the primary site or nodes greater than liver. Likely residual ~~tumor~~tumour.
Focal and intense 18 F-FDG uptake at the primary site or nodes. Residual ~~tumor~~tumour.

-Hopkins head and Neck cancer therapy response interpretation criteria, is a qualitative system of interpretation for therapy response assessment using PET CT. Widely used options for therapy response assessment are clinical examination, histopathology, CT and MR imaging, however have variable diagnostic accuracy. (1,2) 18 F FDG PET/CT is useful in the diagnosis, staging, therapy assessment, and follow-up of Head and neck squamous cell cancer (HNSCC) (3,4).Pretreatment 18F-FDG PET/CT is useful in accurate staging and prediction of disease recurrence as well as survival (5). Post-treatment 18F-FDG PET/CT is useful in evaluating treatment response, detecting recurrence (6), predicting outcomes and survival (7,8). These criteria has a substantial interreader agreement, high negative predictive value, can predict overall survival and progression-free survival in patients with HNSCC.(9) Squamous cell tumors of the head and neck is the most frequent. Strongly associated risk factors (10): - tobacco use. - alcohol consumption. - human papillomavirus (HPV) infection. Five-Point Qualitative Posttherapy Assessment Scoring System (Hopkins Criteria) for Head and Neck PET/CT<ol>
~~-<li>Response category 18 F-FDG uptake at the primary site and nodes less than IJV. Complete metabolic response.</li>~~
~~-<li>Focal 18 F-FDG uptake at the primary site and nodes greater than IJV but less than liver. Likely complete metabolic response.</li>~~
~~-<li>Diffuse 18 F-FDG uptake at the primary site or nodes is greater than IJV or liver. Likely postradiation inflammation.</li>~~
~~-<li>Focal 18 F-FDG uptake at the primary site or nodes greater than liver. Likely residual tumor.</li>~~
~~-<li>Focal and intense 18 F-FDG uptake at the primary site or nodes. Residual tumor.</li>~~
+The head and neck cancer therapy response interpretation (Hopkins criteria) is a qualitative system of interpretation for therapy response assessment using PET-CT.<h4>Background</h4>Widely used options for therapy response assessment are clinical examination, histopathology, CT and MR imaging, however, they have variable diagnostic accuracy 1,2. 18F-FDG PET-CT is useful in the diagnosis, staging, therapy assessment, and follow-up of <a title="Head and neck squamous cell carcinoma (HNSCC)" href="/articles/head-and-neck-squamous-cell-carcinomas">head and neck squamous cell carcinoma (HNSCC)</a> 3,4. Pretreatment 18F-FDG PET-CT is useful in accurate staging and prediction of disease recurrence as well as survival 5. Post-treatment 18F-FDG PET-CT is useful in evaluating treatment response, detecting recurrence 6, predicting outcomes and survival 7,8.These criteria have substantial interreader agreement, high negative predictive value, and can predict overall survival and progression-free survival in patients with HNSCC 9.<h4>Criteria</h4>Five-point qualitative post-therapy assessment scoring system (Hopkins criteria) for head and neck PET-CT:<ol>
+<li>Response category 18F-FDG uptake at the primary site and nodes less than internal jugular vein (IJV). Complete metabolic response.</li>
+<li>Focal 18 F-FDG uptake at the primary site and nodes greater than IJV but less than liver. Likely complete metabolic response.</li>
+<li>Diffuse 18 F-FDG uptake at the primary site or nodes is greater than IJV or liver. Likely postradiation inflammation.</li>
+<li>Focal 18 F-FDG uptake at the primary site or nodes greater than liver. Likely residual tumour.</li>
+<li>Focal and intense 18 F-FDG uptake at the primary site or nodes. Residual tumour.</li>

References changed:

1. Clavel S, Charron MP, Belair M, et al. The role of computed tomography in the management of the neck after chemoradiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012;82:567–573.
2. Vandecaveye V, De Keyzer F, Nuyts S, et al. Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings. Int J Radiat Oncol Biol Phys. 2007;67:960–971.
3. Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med. 2012;53:709–715.
4. Paidpally V, Tahari AK, Lam S, et al. Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years. J Nucl Med. 2013;54:2039–2045.
5. Joo YH, Yoo IR, Cho KJ, et al. Prognostic value of preoperative F-FDG PET/CT for primary head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2014;271:1685–1691.
6. Gupta T, Master Z, Kannan S, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38:2083–2095.
7. Sherriff JM, Ogunremi B, Colley S, Sanghera P, Hartley A. The role of positron emission tomography/CT imaging in head and neck cancer patients after radical chemoradiotherapy. Br J Radiol. 2012;85:e1120–e1126.
8. Cashman EC, MacMahon PJ, Shelly MJ, Kavanagh EC. Role of positron emission tomography–computed tomography in head and neck cancer. Ann Otol Rhinol Laryngol. 2011;120:593–602.
9. Marcus C, Ciarallo A, Tahari A, Mena E, Koch W, Wahl R, Kiess A, Kang H, Subramaniam R. Head and Neck PET/CT: Therapy Response Interpretation Criteria (Hopkins Criteria) −Interreader Reliability, Accuracy, and Survival Outcomes. J Nucl Med. 2014;55:1411-1416.
10. Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S. Head and neck cancer: a global perspective on epidemiology and prognosis. (1998) Anticancer research. 18 (6B): 4779-86. <a href="https://www.ncbi.nlm.nih.gov/pubmed/9891557">Pubmed</a>
1) Clavel S, Charron MP, Belair M, et al. The role of computed tomography in the management of the neck after chemoradiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012;82:567–573.
2) Vandecaveye V, De Keyzer F, Nuyts S, et al. Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings. Int J Radiat Oncol Biol Phys. 2007;67:960–971.
3) Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med. 2012;53:709–715.
4) Paidpally V, Tahari AK, Lam S, et al. Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years. J Nucl Med. 2013;54:2039–2045.
5) Joo YH, Yoo IR, Cho KJ, et al. Prognostic value of preoperative F-FDG PET/CT for primary head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2014;271:1685–1691.
6) Gupta T, Master Z, Kannan S, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38:2083–2095.
7) Sherriff JM, Ogunremi B, Colley S, Sanghera P, Hartley A. The role of positron emission tomography/CT imaging in head and neck cancer patients after radical chemoradiotherapy. Br J Radiol. 2012;85:e1120–e1126.
8) Cashman EC, MacMahon PJ, Shelly MJ, Kavanagh EC. Role of positron emission tomography–computed tomography in head and neck cancer. Ann Otol Rhinol Laryngol. 2011;120:593–602.
9) Marcus C, Ciarallo A, Tahari A, Mena E, Koch W, Wahl R, Kiess A, Kang H, Subramaniam R. Head and Neck PET/CT: Therapy Response Interpretation Criteria (Hopkins Criteria) −Interreader Reliability, Accuracy, and Survival Outcomes. J Nucl Med. 2014;55:1411-1416.
10) Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S. Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res. 1998;18:4779–4786.